Patents by Inventor Mingying He

Mingying He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azalactam Compounds as HPK1 Inhibitors
    Publication number: 20240197703
    Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: May 8, 2023
    Publication date: June 20, 2024
    Applicant: PFIZER INC.
    Inventors: Joyann Barber, Sujin Cho-Schultz, Matthew L. Del Bel, Rebecca Anne Gallego, Mingying He, Mehran Jalaie, Robert Steven Kania, Michele Ann McTigue, Sajiv Krishnan Nair, Anne-Marie Dechert Schmitt, Jamison Bryce Tuttle, Dahui Zhou, Ru Zhou
  • Azalactam compounds as HPK1 inhibitors
    Patent number: 11684616
    Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: June 27, 2023
    Assignee: PFIZER INC.
    Inventors: Joyann Barber, Sujin Cho-Schultz, Matthew L. Del Bel, Rebecca Anne Gallego, Mingying He, Mehran Jalaie, Robert Steven Kania, Michele Ann McTigue, Sajiv Krishnan Nair, Anne-Marie Dechert Schmitt, Jamison Bryce Tuttle, Dahui Zhou, Ru Zhou
  • Azalactam Compounds as HPK1 Inhibitors
    Publication number: 20220401424
    Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: April 30, 2021
    Publication date: December 22, 2022
    Applicant: PFIZER INC.
    Inventors: Joyann Barber, Sujin Cho-Schultz, Matthew L. Del Bel, Rebecca Anne Gallego, Mingying He, Mehran Jalaie, Robert Steven Kania, Michele Ann McTigue, Sajiv Krishnan Nair, Anne-Marie Dechert Schmitt, Jamison Bryce Tuttle, Dahui Zhou, Ru Zhou
  • Azalactam compounds as HPK1 inhibitors
    Patent number: 11142525
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: October 12, 2021
    Assignee: PFIZER INC.
    Inventors: Rebecca Anne Gallego, Sajiv Krishnan Nair, Robert Steven Kania, Omar Khaled Ahmad, Ted William Johnson, Jamison Bryce Tuttle, Mehran Jalaie, Michele Ann McTigue, Dahui Zhou, Matthew L. Del Bel, Ru Zhou, Mingying He, Anne-Marie Dechert Schmitt
  • Azalactam Compounds as HPK1 Inhibitors
    Publication number: 20200172539
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: November 11, 2019
    Publication date: June 4, 2020
    Applicant: Pfizer Inc.
    Inventors: Rebecca Anne Gallego, Sajiv Krishnan Nair, Robert Steven Kania, Omar Khaled Ahmad, Ted William Johnson, Jamison Bryce Tuttle, Mehran Jalaie, Michele Ann McTigue, Dahui Zhou, Matthew L. Del Bel, Ru Zhou, Mingying He
  • Alkoxy-substituted 2-aminopyridines as ALK inhibitors
    Patent number: 8916593
    Abstract: The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: December 23, 2014
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Bunnage, Andrew Simon Cook, Jingrong Jean Cui, Kevin Nell Dack, Judith Gail Deal, Danlin Gu, Mingying He, Patrick Stephen Johnson, Ted William Johnson, Phuong Thi Quy Le, Cynthia Louise Palmer, Hong Shen
  • HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
    Publication number: 20130196952
    Abstract: The invention relates to compounds of Formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 1, 2013
    Applicant: PFIZER INC.
    Inventors: Mark Edward Bunnage, Andrew Simon Cook, Jingrong Jean Cui, Kevin Nell Dack, Judith Gail Deal, Danlin Gu, Mingying He, Patrick Stephen Johnson, Ted William Johnson, Phuong Thi Quy Le, Cynthia Louise Palmer, Hong Shen
  • Fused phenyl amido heterocyclic compounds
    Patent number: 8119624
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R1, R1a, R2, R3, R4, L2, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: February 21, 2012
    Assignee: Pfizer Inc.
    Inventors: Hao Bai, Simon Bailey, Dilip Ramakant Bhumralkar, Feng C. Bi, Fengli Guo, Mingying He, Paul Stuart Humphries, Anthony Lai Ling, Jihong Lou, Seiji Nukui, Ru Zhou
  • Fused Phenyl Amido Heterocyclic Compounds
    Publication number: 20110039821
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R1, R1a, R2, R3, R4, L2, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).
    Type: Application
    Filed: October 27, 2010
    Publication date: February 17, 2011
    Inventors: Hao Bai, Simon Bailey, Dilip Ramakant Bhumralkar, Feng C. Bi, Fengli Guo, Mingying He, Paul Stuart Humphries, Anthony Lai Ling, Jihong Lou, Seiji Nukui, Ru Zhou
  • Fused phenyl amido heterocyclic compounds
    Patent number: 7842713
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R1, R1a, R2, R3, R4, L2, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: November 30, 2010
    Assignee: Pfizer Inc
    Inventors: Hao Bai, Simon Bailey, Dilip Ramakant Bhumralkar, Feng C. Bi, Fengli Guo, Mingying He, Paul Stuart Humphries, Anthony Lai Ling, Jihong Lou, Seiji Nukui, Ru Zhou
  • FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS
    Publication number: 20080280875
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R1, R1a, R2, R3, R4, L2, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).
    Type: Application
    Filed: May 9, 2007
    Publication date: November 13, 2008
    Inventors: Hao Bai, Simon Bailey, Dilip Ramakant Bhumralkar, Feng C. Bi, Fengli Guo, Mingying He, Paul Stuart Humphries, Anthony Lai Ling, Jihong Lou, Seiji Nukul, Ru Zhou
  • Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents
    Patent number: 7208500
    Abstract: The invention relates to compounds represented by Formula (I): and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein each of X1–X5 and R1–R5 are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: April 24, 2007
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Jihong Lou, Robert Steven Kania, Mingying He
  • Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
    Patent number: 7045528
    Abstract: The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: May 16, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michael Collins, Stephan Cripps, Judith Deal, Robert Steven Kania, Jihong Lou, Mingying He, Cynthia Louise Palmer, William Henry Romines, III, Ru Zhou
  • Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
    Publication number: 20060079548
    Abstract: The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
    Type: Application
    Filed: October 21, 2005
    Publication date: April 13, 2006
    Inventors: Michael Collins, Stephan Cripps, Judith Deal, Robert Kania, Jihong Lou, Mingying He, Cynthia Palmer, William Romines, Ru Zhou
  • Inhibitors of SARS 3C like protease
    Publication number: 20060014821
    Abstract: The invention relates to methods of inhibiting SARS-related coronavirus viral replication activity comprising contacting a SARS-related coronavirus protease with a therapeutically effective amount of a SARS 3C like protease inhibitor, and compositions comprising the same.
    Type: Application
    Filed: August 13, 2004
    Publication date: January 19, 2006
    Inventors: Mingying He, Robert Kania, Jihong Lou, Simon Planken
  • Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents
    Publication number: 20050090509
    Abstract: The invention relates to compounds represented by Formula (I): and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein each of X1-X5 and R1-R5 are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
    Type: Application
    Filed: August 26, 2004
    Publication date: April 28, 2005
    Inventors: Jihong Lou, Robert Kania, Mingying He
  • Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents
    Publication number: 20050070508
    Abstract: The invention relates to compounds represented by Formula (I): and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein each of R1a-d, R2a-b, R3, and X1 are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
    Type: Application
    Filed: August 23, 2004
    Publication date: March 31, 2005
    Inventors: Jihong Lou, Robert Kania, Mingying He, Ru Zhou
  • Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
    Patent number: 6869962
    Abstract: The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: March 22, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michael Collins, Stephan Cripps, Judith Deal, Robert Steven Kania, Jihong Lou, Mingying He, Cynthia Louise Palmer, William Henry Romines, III, Ru Zhou
  • Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use
    Patent number: 6833456
    Abstract: The invention relates to compounds represented by the formula I and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein X, R1 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: December 21, 2004
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: William Henry Romines, III, Robert Steven Kania, Jihong Lou, Stephan Cripps, Ru Zhou, Mingying He
  • Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
    Publication number: 20040186126
    Abstract: The invention relates to compounds represented by the formula I 1
    Type: Application
    Filed: March 9, 2004
    Publication date: September 23, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Michael Collins, Stephan Cripps, Judith Deal, Robert Steven Kania, Jihong Lou, Mingying He, Cynthia Louise Palmer, William Henry Romines, Ru Zhou